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Abstract
X-linked recessive type chondrodysplasia punctata (CDPX1) is a congenital disorder of cartilage and bone development
with typical findings of stippled epyphises, nasomaxillary hypoplasia and short distal phalanges in a male patient.
Disease is caused due to the loss of arylsulfatase E activity and only 55 patients with genetically confirmed disease have
been reported so far. In 60–75 % of all patients the mutation in ARSE gene is detected by sequence analysis and in
further 25 % of patients Xp deletions or rearrangements are causative and may be identified by classical chromosome
studies. We report on a male patient refered to clinical geneticist for congenital hearing loss and mild dysplastic signs,
both phenotypic features being relatively unspecific and non suggestive of CDPX1 in first instance. Array comparative
genomic hybridisation showed approximatelly 3 kb big deletion, spaning intron and exon 7 of arylsulfatase E gene
located in Xp22.33. This explained the cause of hearing loss, being present in 26–89 % od CDPX1 patients, as well as
additional non prominent skeletal characteristics described by geneticist in our patient - mild midface hypoplasia and
mild brachytelephalangy. Reported case introduces different presenting clinical phenotype for CDPX1, emphasizing
different expressivity in this disorder.
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Background
Chondrodysplasia punctata (CDP) is a heterogeneous
group of bone disorders, clinically and genetically diverse.
Typical characteristic is punctiform calcification of the
bones. With different combination of additional features,
there are now 5 forms with known genetic cause. No
classification consensus has been established. There
are 3 autosomal recessive rhizomelic forms (RCDP1
OMIM#302960, RCDP2 OMIM#222765 and RCDP3
OMIM#600121), one X-linked dominant form (CDPX2
OMIM#215100) and here reported and reviewed X-linked
recessive CDPX1 (OMIM#302950), consequence of muta-
tions in ARSE gene (OMIM*300180) at Xp22.33. Due to
the characteristic short distal phalanges, it is reffered to as
brachytelephalangic chondrodysplasia punctata (BCP).
Typical findings in this group of skeletal dysplasia are
stippled epyphises (chondrodysplasia punctata), naso-
maxillary hypoplasia (Binder phenotype) and short distal
phalanges (brachytelephalangy). Interestingly, both ac-
quired and genetic causes have been described, presenting
with similar phenotype [1, 2]. Metabolic abnormalities
include disorders in peroxisomal metabolism, lysosomal
storage disorders, disturbed cholesterol biosynthesis and
disruption of vitamin K metabolism. Gene ARSE codes
for arylsulfatase-E, vitamin K dependent enzyme, and its
activity is inhibited in the presence of warfarin, an anti-
coagulant drug that decreases amounts of active vitamin
K. Therefore, warfarin exposure and vitamin K deficiency
present logical phenocopies of CDPX1 and there are case
reports described confirming this [2, 3]. In addition, it was
known already in late 1970s that warfarin treatment dur-
ing pregnancy can cause nasal hypoplasia, stippled epiphy-
ses and vertebral defects in fetuses [4].
The ARSE gene is located at Xp22.33, within a cluster of
contiguous arylsulfatase genes, that share high sequence
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homology, escape X inactivation, and have pseudo-
genes on the Y chromosome [5]. ARSE is localized to the
Golgi membranes and its transcript has been identified in
multiple tissues [6]. Most affected males have minimal
morbidity with normal intellect and life span and skeletal
findings typically diminishing by adulthood. In contrast to
relatively mild morbidity in most males, additional medical
problems such as short stature, mixed conductive and sen-
sorineural hearing loss, abnormal cognitive development,
and possibly significant complications such as airway sten-
osis and cervical spine instability with compression of the
cervical spine cord, have been described in some cases.
Typical X-ray finding of punctate epyphises is not obliga-
tory and frequently only present in early childhood.
By now around 140 male patients with a clinical
phenotype had been reported, but genetic cause has
been confirmed in less than half. In 60–75 % of CDPX1
cases, reported genetic cause is detected by sequence
analysis of ARSE gene, in further 25 % of patients Xp de-
letions or rearrangements are identified on classical
chromosome studies [6]. Smaller deletions can be evalu-
ated by array CGH. In the group of patients with dele-
tions, only one case of single exon deletion has been
reported, deletion of exon 10 in a severly affected patient
[7]. There is a case of deletion of exons 1 and 2 with se-
vere clinical presentation as well [3]. Appart from that,
only large deletions, including the whole ARSE gene had
been reported [8]. All the mothers of genetically con-
firmed cases, that were tested, were reported to be carriers
of point mutation or deletions. There is no case of con-
firmed de novo mutation in the literature reported so far.
Here we report a new case in the terms of clinical
presentation and mutation type/size. Namely, male pa-
tient was refered to clinical geneticist for congenital
hearing loss and mild dysplastic signs and array CGH
showed deletion of intron and exon 7 in ARSE gene.
Case presentation
Patient
9 year old boy was reffered to Clinical Institute of
Medical Genetics Ljubljana because of mixed sensori-
neural hearing loss and mild dysplastic signs. He was
born as a first child to unrelated healthy parents after
uneventful pregnancy, with normal birth parameters
(birth weight at 60th percentile, birth length at 70th per-
centile) and APGAR score 9/9/10. Screening test for
newborns showed congenital hearing loss. Brain stem
acustic potential evaluation identified mixed sensori-
neural hearing loss at age 13 days. General examination
revealed nasomaxillary hypoplasia and mild hypotonia,
which persisted until one year of age. Further medical
exams including brain ultrasound, abdominal ultrasound,
CT of temporal bones and eye examination revealed no
further abnormalities. All developmental milestones where
achieved as expected. Family history was uneventful for
genetic diseases, skeletal abnormalities, congenital anom-
alies and hearing loss. At the age of 9 years, clinical geneti-
cist described high forehead, midfacial hypoplasia with
mild hypertelorism, hypoplastic nose, depressed nasal
bridge and long philtrum.
Genetic testing
Chromosome analysis in 2005 showed normal male karyo-
type 46, XY. Molecular genetic analysis for hearing loss in
2008, ordered by otorhinolaryngologist, monitoring the
boy's hearing, did not identify any mutations in GJB2 and
GJB6 genes, which excluded the most common cause of
genetic nonsyndromic hearing loss. Namely, mutations in
mentioned genes are reported to be found in 33,0 % of
children with hearing loss in Slovenia [9]. After seeing the
patient when he was 9 years old, array CGH was per-
formed and showed minimum 2886 bp large deletion,
spaning intron and exon 7 of ARSE gene (arr[hg19]
Fig. 1 Array CGH results in reported case (left panel) and his mother (right panel). Hemizygous deletion in the boy shows higher relative number
values (between −2 and −3) compared to heterozygous deletion in the mother (around −0.8 and −1)
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Xp22.33(2,861,119×1,2,861,384-2,864,270×0,2,865,276×1)).
Proximal breakpoint and next available microarray probe
was only 265 bp away, distal next available probe was
1006 bp away. Mother was deletion carrier, as well (Fig. 1).
Overview of reported genetic variants
There are 55 patients with CDPX1 reported so far [8].
Seven patients have deletion of the full ARSE gene, one
patient has exon 1–2 deletion, 2 patients (brothers) have
exon 7–10 deletions and one has only exon 10 deletion.
Together with here reported case, 12/56 (21 %) cases
have partial or whole gene deletions. There is one re-
ported case with triplet deletion in exon 3 and two cases
with duplication of single nucleotide. All others have
point mutations. Vast majority of reported mutations are
private family mutations (Table 1). Although reported
mutations are distributed throughout the gene, except
for exon 1 and 2 where there is no reported point muta-
tions, it seems that mutations in exon 5 and exon 11 are
more frequently reported. When looking at reported
cases with point mutation/single nucleotide changes,
there are 7/43 (16 %) and 14/43 (33 %) reported cases
with mutation in exon 5 and exon 11, respectively.
Discussion and conclusion
Typical combination of signs of CDPX1 is stippled epy-
phises, nasomaxillary hypoplasia and short distal phalan-
ges in a male patient. This was not so obvious in our
patient, who was refered to us because of congenital
hearing loss and mild dysplastic signs (those being in
concordance with typical signs of CDPX1) and was
found to have a small intragenic ARSE deletion by array
CGH. At the time of examination, we would not expect
the signs of chondrodysplasia punctata, as it can be ob-
served already in the second trimester of pregnancy, but
tends to improve and even disappear by age 2–3 years.
The disease is relatively rarely reported - there are only
56 described patients, including our case - and pheno-
typic spectrum is broad. One might speculate that it is
different, according to the type, location and size of gen-
etic defect. About 1/5 of cases have partial or whole
gene deletions detectable with array-CGH and previ-
ously reported larger deletions with classical cytogenet-
ics. The remainder of genetically confirmed cases have
point mutations or single nucleotide insertions and
therefore need sequence analysis to confirm the genetic
cause. About 1/3 of reported point mutation/single nu-
cleotide changes are located in exon11. There are two
possible explanations - firstly, exon might be more prone
to mutations due to so far unknown reasons or, more
likely, mutations in exon11 present with more specific
and severe clinical symptoms and therefore bring pro-
portionally more affected males to medical attention and
further investigations. To support this, there are six
reported cases with severe symptoms and confirmed sin-
gle nucleotide ARSE mutation so far [7, 10], all mutation
being in exon 11. Three born patients had significant re-
spiratory distress requiring assisted ventilation due to
cervical spinal canal stenosis and related spinal cord
compression. Three cases were aborted in late second
trimester when severe spinal canal stenosis was seen.
There are 2 additional clinical reports of newborn males,
both with cervical spinal canal stenosis and typical
radiographic chondrodysplasia punctata, flat nasal bridge
Table 1 Reported mutations in ARSE gene
Exon Mutation Number of patients Inherited
00_02i Exons 1–2 deletion 1 +
00_11 Whole gene deletion 7 +
3 c.36G > C 1 +
3 c.119 T > G 2 +
3 c.126_128delTCT 1 NA
3 c.169G > A 1 NA
02i_03i Exon 3 deletion 1 +
4 c.217G > A 1 +
4 c.239 T > A 1 +
4 c.268A > G 1 NA
5 c.314dupT 1 NA
5 c.332G > C 1 +
5 c.349G > A 1 NA
5 c.345G > A 1 NA
5 c.410G > C 3 +
5 c.410G > T 1 NA
6 c.445G > T 1 NA
6 c.733G > C 1 NA
6 c.767dupT 1 +
06i_10i Exons 7–10 deletion 2 +
7 c.916A > G 1 NA
7 c.949G > A 2 +
8 c.1063G > A 1 NA
9 c.1130G > A 2 +
9 c.1171G > A 1 +
9 c.1226C > T 1 +
09i_10i Exon 10 deletion 1 NA
10 c.1300G > A 2 +
10 c.1387G > A 1 NA
11 c.1442C > T 4 +
11 c.1475G > A 1 NA
11 c.1618C > T 1 NA
11 c.1732C > T 2 +
11 c.1743G > A 6 +
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and brachytelephalangy, but no molecular genetic testing
has been performed [11].
On the other side of phenotypic spectrum, there are
mild cases. Typical radiographic signs (punctate epy-
phises) are frequently only present in early childhood
and after that only minor signs might be present and
therefore go unrecognised. Some cases were described
with only shortened distal phalanges and mild midfacial
hypoplasia [1]. Delayed motor and cognitive develop-
ment are reporeted in 19–33 % and 16–20 % of cases,
respectively [3, 6]. Also, fertility is normal. For both rea-
sons, family mutations might spread to next generations,
not only through healthy female mutation carriers, but
through affected (undiagnosed) males, as well. It was re-
ported in a family with mild phenotypic presentation,
that maternal uncle with no major health issues, was a
mutation carrier as well [12]. Unfortunatelly, other fam-
ily members were not available for testing in our case.
In addition to genetic cause, important maternal etio-
logical factors have been linked to the phenotype (warfarine
exposure, vitamin K deficiency, maternal autoimmune
disease), but still around 40 % of male patients with bra-
chytelephalangic chondrodysplasia punctata do not have
detectable ARSE mutations or known maternal etiological
factors [3, 6]. Further understanding of mechanism behind
ARSE function might prove useful in identifying other
potential candidates in the same disturbed pathway that,
when defective, would lead to the similar phenotype of bra-
chytelephalangic chondrodysplasia punctata. As already
mentioned, these may involve maternal-fetal vitamin K defi-
ciency, with warfarin embryopathy being known for de-
cades. Already in late 1970s it was reported that fetuses of
women treated with warfarin during pregnancy, are at in-
creased risk for nasal hypoplasia, stippled epiphyses and ver-
tebral defects [4]. Maternal systemic lupus erythematosus
has been reported to be a risk factor for the same phenotype
in fetus, as well [13]. Not all fetuses exposed to warfarin or
born to mothers with SLE develop CDP typical signs, and
further knowledge of mechanisms behind this phenotype is
needed to help elucidate all the causes behind it.
To conclude, we present a case of X-linked recessive
chondrodysplasia punctata (CDPX1), interesting for two
reasons. Firstly, this is the first case, diagnosed with
array CGH and found to have a deletion of intron7 and
exon7 in ARSE gene. Secondly, this is also the first case
to present with congenital sensorineural hearing loss
and mild facial dysmorphisms at the age of 9 as major
clinical signs. With this case we add to clinical and gen-
etic spectrum of CDPX1.
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